New: Clinical trial search, funded by the National Cancer InstituteNew: NCI-funded clinical trial search

Would you offer adjuvant endocrine therapy to a male with ER+ DCIS?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

What are your top takeaways in Medical Oncology from SABCS 2025?

How do the ALTTO trial findings influence your choice of adjuvant endocrine therapy (AI with or without ovarian function suppression versus SERM-based therapy) for patients with HR+/HER2+ early breast cancer?

Based on the recent IRIS-A trial presented at ASCO 2026, would adjuvant capecitabine plus trastuzumab be a reasonable consideration for a premenopausal patient with a unifocal, microinvasive (0.7 mm), ER/PR-positive, HER2-positive invasive ductal carcinoma (pT1miN0)?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 24 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
TrialMatch
Mobile App

Company

About
Careers
Events
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.